Philip J. Rosenfeld, M.D., Ph.D.

Acucela Inc., a Seattle-based clinical-stage biotech company focused on developing new treatments for blinding eye diseases, announces that Philip D. Rosenfeld, M.D., Ph.D., has joined the Clinical Advisory Board for ACU-4429, its lead compound.